The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria

Journal of Allergy and Clinical Immunology

Volumn 135, Issue 2, 2015, Pages 337-342.e2

  Chang, Tse Wen ^a   Chen, Christina ^a   Lin, Chien Jen ^a   Metz, Martin ^b   Church, Martin K ^b   Maurer, Marcus ^b  

^a GENOMICS RESEARCH CENTER   (Taiwan)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

activation release threshold; autoantibodies; Chronic urticaria; Fc RI; IgE; IgE Fc RI mast cell axis; mast cells; omalizumab

Indexed keywords

IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; OMALIZUMAB; ALLERGEN; ANTIALLERGIC AGENT; ANTIIDIOTYPIC ANTIBODY; MONOCLONAL ANTIBODY;

ALLERGIC DISEASE; ARTICLE; BASOPHIL; CELL ACTIVATION; CELL ACTIVITY; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC SPONTANEOUS URTICARIA; CHRONIC URTICARIA; CROSS LINKING; DRUG MECHANISM; DRUG POTENCY; DRUG RESPONSE; HUMAN; MAST CELL; MAST CELL DEGRANULATION; MEDIATOR; MEDIATOR RELEASE; PRIORITY JOURNAL; AUTOIMMUNITY; CHRONIC DISEASE; DEGRANULATION; DRUG EFFECTS; HISTAMINE RELEASE; IMMUNOLOGY; METABOLISM; TREATMENT OUTCOME; URTICARIA;

ALLERGENS; ANTI-ALLERGIC AGENTS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL, HUMANIZED; AUTOIMMUNITY; CELL DEGRANULATION; CHRONIC DISEASE; HISTAMINE RELEASE; HUMANS; IMMUNOGLOBULIN E; MAST CELLS; TREATMENT OUTCOME; URTICARIA;

EID: 84922343034     PISSN: 00916749     EISSN: 10976825     Source Type: Journal    
DOI: 10.1016/j.jaci.2014.04.036     Document Type: Review

References (76)

1. T. Zuberbier, R. Asero, C. Bindslev-Jensen, G. Walter Canonica, M.K. Church, and A. Gimenez-Arnau EAACI/GA(2)LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria Allergy 64 2009 1417 1426
2. P. Staubach, M. Dechene, M. Metz, M. Magerl, F. Siebenhaar, and K. Weller High prevalence of mental disorders and emotional distress in patients with chronic spontaneous urticaria Acta Derm Venereol 91 2011 557 561
3. T. Zuberbier, R. Asero, C. Bindslev-Jensen, G. Walter Canonica, M.K. Church, and A.M. Gimenez-Arnau EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria Allergy 64 2009 1427 1443
4. S.L. Spector, and R.A. Tan Effect of omalizumab on patients with chronic urticaria Ann Allergy Asthma Immunol 99 2007 190 193
5. A.P. Kaplan, K. Joseph, R.J. Maykut, G.P. Geba, and R.K. Zeldin Treatment of chronic autoimmune urticaria with omalizumab J Allergy Clin Immunol 122 2008 569 573
6. M.F. Sands, J.W. Blume, and S.A. Schwartz Successful treatment of 3 patients with recurrent idiopathic angioedema with omalizumab J Allergy Clin Immunol 120 2007 979 981
7. J.A. Boyce Successful treatment of cold-induced urticaria/anaphylaxis with anti-IgE J Allergy Clin Immunol 117 2006 1415 1418
8. M. Metz, P. Bergmann, T. Zuberbier, and M. Maurer Successful treatment of cholinergic urticaria with anti-immunoglobulin E therapy Allergy 63 2008 247 249
9. O. Guzelbey, E. Ardelean, M. Magerl, T. Zuberbier, M. Maurer, and M. Metz Successful treatment of solar urticaria with anti-immunoglobulin E therapy Allergy 63 2008 1563 1565
10. S. Saini, K.E. Rosen, H.J. Hsieh, D.A. Wong, E. Conner, and A. Kaplan A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria J Allergy Clin Immunol 128 2011 567 573.e1
11. M. Maurer, S. Altrichter, T. Bieber, T. Biedermann, M. Brautigam, and S. Seyfried Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase J Allergy Clin Immunol 128 2011 202 209.e5
12. M. Maurer, K. Rosen, H.J. Hsieh, S. Saini, C. Grattan, and A. Gimenez-Arnau Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria N Engl J Med 368 2013 924 935
13. A. Kaplan, D. Ledford, M. Ashby, J. Canvin, J.L. Zazzali, and E. Conner Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy J Allergy Clin Immunol 132 2013 101 109
14. M. Metz, T. Ohanyan, M.K. Church, and M. Maurer Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis J Dermatol Sci 73 2014 57 62
15. T.W. Chang The pharmacological basis of anti-IgE therapy Nat Biotechnol 18 2000 157 162
16. T.W. Chang, P.C. Wu, C.L. Hsu, and A.F. Hung Anti-IgE antibodies for the treatment of IgE-mediated allergic diseases Adv Immunol 93 2007 63 119
17. T.W. Chang, and Y.Y. Shiung Anti-IgE as a mast cell-stabilizing therapeutic agent J Allergy Clin Immunol 117 2006 1203 1213
18. G.W. Read, and D. Lagunoff Antagonism of the final common pathway of mast cell histamine secretion by arylalkylamines J Pharmacol Exp Ther 237 1986 357 363
19. K.P. Mathews The urticarias. Current concepts in pathogenesis and treatment Drugs 30 1985 552 560
20. A.P. Kaplan, Z. Horakova, and S.I. Katz Assessment of tissue fluid histamine levels in patients with urticaria J Allergy Clin Immunol 61 1978 350 354
21. D.D. Metcalfe Mast cells and mastocytosis Blood 112 2008 946 956
22. A.P. Kaplan Chronic urticaria: pathogenesis and treatment J Allergy Clin Immunol 114 2004 465 475
23. K.D. Alysandratos, S. Asadi, A. Angelidou, B. Zhang, N. Sismanopoulos, and H. Yang Neurotensin and CRH interactions augment human mast cell activation PLoS One 7 2012 e48934
24. K. Asai, J. Kitaura, Y. Kawakami, N. Yamagata, M. Tsai, and D.P. Carbone Regulation of mast cell survival by IgE Immunity 14 2001 791 800
25. J. Kalesnikoff, M. Huber, V. Lam, J.E. Damen, J. Zhang, and R.P. Siraganian Monomeric IgE stimulates signaling pathways in mast cells that lead to cytokine production and cell survival Immunity 14 2001 801 811
26. M. Jayapal, H.K. Tay, R. Reghunathan, L. Zhi, K.K. Chow, and M. Rauff Genome-wide gene expression profiling of human mast cells stimulated by IgE or FcepsilonRI-aggregation reveals a complex network of genes involved in inflammatory responses BMC Genomics 7 2006 210
27. J. Kitaura, J. Song, M. Tsai, K. Asai, M. Maeda-Yamamoto, and A. Mocsai Evidence that IgE molecules mediate a spectrum of effects on mast cell survival and activation via aggregation of the FcepsilonRI Proc Natl Acad Sci U S A 100 2003 12911 12916
28. T. Kawakami, and J. Kitaura Mast cell survival and activation by IgE in the absence of antigen: a consideration of the biologic mechanisms and relevance J Immunol 175 2005 4167 4173
29. J. Kashiwakura, Y. Okayama, M. Furue, K. Kabashima, S. Shimada, and C. Ra Most highly cytokinergic IgEs have polyreactivity to autoantigens Allergy Asthma Immunol Res 4 2012 332 340
30. R. Confino-Cohen, G. Chodick, V. Shalev, M. Leshno, O. Kimhi, and A. Goldberg Chronic urticaria and autoimmunity: associations found in a large population study J Allergy Clin Immunol 129 2012 1307 1313
31. R.A. Sabroe, P.T. Seed, D.M. Francis, R.M. Barr, A.K. Black, and M.W. Greaves Chronic idiopathic urticaria: comparison of the clinical features of patients with and without anti-FcepsilonRI or anti-IgE autoantibodies J Am Acad Dermatol 40 1999 443 450
32. C.E. Grattan, T.B. Wallington, R.P. Warin, C.T. Kennedy, and J.W. Bradfield A serological mediator in chronic idiopathic urticaria - a clinical, immunological and histological evaluation Br J Dermatol 114 1986 583 590
33. R.C. Benyon The human skin mast cell Clin Exp Allergy 19 1989 375 387
34. G.N. Konstantinou, R. Asero, M. Maurer, R.A. Sabroe, P. Schmid-Grendelmeier, and C.E. Grattan EAACI/GA(2)LEN task force consensus report: the autologous serum skin test in urticaria Allergy 64 2009 1256 1268
35. P. Staubach, A. Vonend, G. Burow, M. Metz, M. Magerl, and M. Maurer Patients with chronic urticaria exhibit increased rates of sensitisation to Candida albicans, but not to common moulds Mycoses 52 2009 334 338
36. A. Leznoff, R.G. Josse, J. Denburg, and J. Dolovich Association of chronic urticaria and angioedema with thyroid autoimmunity Arch Dermatol 119 1983 636 640
37. D. Zauli, G. Deleonardi, S. Foderaro, A. Grassi, R. Bortolotti, and G. Ballardini Thyroid autoimmunity in chronic urticaria Allergy Asthma Proc 22 2001 93 95
38. K.S. Wan, and C.S. Wu The essential role of anti-thyroid antibodies in chronic idiopathic urticaria Endocr Res 38 2013 85 88
39. S. Altrichter, H.J. Peter, D. Pisarevskaja, M. Metz, P. Martus, and M. Maurer IgE mediated autoallergy against thyroid peroxidase - a novel pathomechanism of chronic spontaneous urticaria? PLoS One 6 2011 e14794
40. Y. Hatada, J. Kashiwakura, K. Hayama, D. Fujisawa, T. Sasaki-Sakamoto, and T. Terui Significantly high levels of anti-dsDNA immunoglobulin E in sera and the ability of dsDNA to induce the degranulation of basophils from chronic urticaria patients Int Arch Allergy Immunol 161 suppl 2 2013 154 158
41. S.D. Chakravarty, A.F. Yee, and S.A. Paget Rituximab successfully treats refractory chronic autoimmune urticaria caused by IgE receptor autoantibodies J Allergy Clin Immunol 128 2011 1354 1355
42. P.D. Arkwright Anti-CD20 or anti-IgE therapy for severe chronic autoimmune urticaria J Allergy Clin Immunol 123 2009 510 511 author reply 1
43. J.A. Bernstein, S.M. Garramone, and E.G. Lower Successful treatment of autoimmune chronic idiopathic urticaria with intravenous cyclophosphamide Ann Allergy Asthma Immunol 89 2002 212 214
44. R. Asero Oral cyclophosphamide in a case of cyclosporin and steroid-resistant chronic urticaria showing autoreactivity on autologous serum skin testing Clin Exp Dermatol 30 2005 582 583
45. C.L. Hsu, Y.Y. Shiung, B.L. Lin, H.Y. Chang, and T.W. Chang Accumulated immune complexes of IgE and omalizumab trap allergens in an in vitro model Int Immunopharmacol 10 2010 533 539
46. M.R. Stampfli, S. Miescher, I. Aebischer, A.W. Zurcher, and B.M. Stadler Inhibition of human IgE synthesis by anti-IgE antibodies requires divalent recognition Eur J Immunol 24 1994 2161 2167
47. F.M. Davis, L.A. Gossett, K.L. Pinkston, R.S. Liou, L.K. Sun, and Y.W. Kim Can anti-IgE be used to treat allergy? Springer Semin Immunopathol 15 1993 51 73
48. M.A. Chan, N.M. Gigliotti, A.L. Dotson, and L.J. Rosenwasser Omalizumab may decrease IgE synthesis by targeting membrane IgE+ human B cells Clin Transl Allergy 3 2013 29
49. P.J. Lowe, and D. Renard Omalizumab decreases IgE production in patients with allergic (IgE-mediated) asthma; PKPD analysis of a biomarker, total IgE Br J Clin Pharmacol 72 2011 306 320
50. R.G. Slavin, C. Ferioli, S.J. Tannenbaum, C. Martin, M. Blogg, and P.J. Lowe Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations J Allergy Clin Immunol 123 2009 107 113.e3
51. K.F. Rabe, W.J. Calhoun, N. Smith, and P. Jimenez Can anti-IgE therapy prevent airway remodeling in allergic asthma? Allergy 66 2011 1142 1151
52. S.L. Spector, and R.A. Tan Effect of omalizumab on patients with chronic urticaria Ann Allergy Asthma Immunol 99 2007 190 193
53. A.P. Kaplan, K. Joseph, R.J. Maykut, G.P. Geba, and R.K. Zeldin Treatment of chronic autoimmune urticaria with omalizumab J Allergy Clin Immunol 122 2008 569 573
54. K.V. Godse Omalizumab in severe chronic urticaria Indian J Dermatol Venereol Leprol 74 2008 157 158
55. J.F. Maspero, C.A. Parisi, M. De Gennaro, O. Benhabib, and M. Lampert [Chronic autoimmune urticaria: treatment with omalizumab] Arch Argent Pediatr 107 2009 452 456
56. M. Magerl, P. Staubach, S. Altrichter, E. Ardelean, K. Krause, and M. Metz Effective treatment of therapy-resistant chronic spontaneous urticaria with omalizumab J Allergy Clin Immunol 126 2010 665 666
57. E. Iemoli, S. Piconi, A. Fusi, L. Borgonovo, M. Borelli, and D. Trabattoni Immunological effects of omalizumab in chronic urticaria: a case report J Investig Allergol Clin Immunol 20 2010 252 254
58. C. Vestergaard, and M. Deleuran Two cases of severe refractory chronic idiopathic urticaria treated with omalizumab Acta Derm Venereol 90 2010 443 444
59. C. Romano, A. Sellitto, U. De Fanis, G. Esposito, P. Arbo, and R. Giunta Maintenance of remission with low-dose omalizumab in long-lasting, refractory chronic urticaria Ann Allergy Asthma Immunol 104 2010 95 97
60. M. Al-Ahmad Omalizumab therapy in three patients with chronic autoimmune urticaria Ann Saudi Med 30 2010 478 481
61. A. Groffik, H. Mitzel-Kaoukhov, M. Magerl, M. Maurer, and P. Staubach Omalizumab - an effective and safe treatment of therapy-resistant chronic spontaneous urticaria Allergy 66 2011 303 305
62. M. Ferrer, P. Gamboa, M.L. Sanz, M.J. Goikoetxea, P. Cabrera-Freitag, and G. Javaloyes Omalizumab is effective in nonautoimmune urticaria J Allergy Clin Immunol 127 2011 1300 1302
63. M. Maurer, S. Altrichter, T. Bieber, T. Biedermann, M. Brautigam, and S. Seyfried Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase J Allergy Clin Immunol 128 2011 202 209.e5
64. K.V. Godse Omalizumab in treatment-resistant chronic spontaneous urticaria Indian J Dermatol 56 2011 444
65. S. Saini, K.E. Rosen, H.J. Hsieh, D.A. Wong, E. Conner, and A. Kaplan A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria J Allergy Clin Immunol 128 2011 567 573.e1
66. S. Buyukozturk, A. Gelincik, M. Demirturk, E. Kocaturk, B. Colakoglu, and M. Dal Omalizumab markedly improves urticaria activity scores and quality of life scores in chronic spontaneous urticaria patients: a real life survey J Dermatol 39 2012 439 442
67. I. Ivyanskiy, C. Sand, and S.F. Thomsen Omalizumab for chronic urticaria: a case series and overview of the literature Case Rep Dermatol 4 2012 19 26
68. M. Metz, T. Ohanyan, M.K. Church, and M. Maurer Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis J Dermatol Sci 73 2014 57 62
69. C.H. Song, S. Stern, M. Giruparajah, N. Berlin, and G.L. Sussman Long-term efficacy of fixed-dose omalizumab for patients with severe chronic spontaneous urticaria Ann Allergy Asthma Immunol 110 2013 113 117
70. M. Maurer, K. Rosen, H.J. Hsieh, S. Saini, C. Grattan, and A. Gimenez-Arnau Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria N Engl J Med 368 2013 924 935
71. A.C. Lefevre, M. Deleuran, and C. Vestergaard A long term case series study of the effect of omalizumab on chronic spontaneous urticaria Ann Dermatol 25 2013 242 245
72. M. Armengot-Carbo, M. Velasco-Pastor, B. Rodrigo-Nicolas, V. Pont-Sanjuan, E. Quecedo-Estebanez, and E. Gimeno-Carpio Omalizumab in chronic urticaria: a retrospective series of 15 cases Dermatol Ther 26 2013 257 259
73. A. Kaplan, D. Ledford, M. Ashby, J. Canvin, J.L. Zazzali, and E. Conner Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy J Allergy Clin Immunol 132 2013 101 109
74. M. Labrador-Horrillo, A. Valero, M. Velasco, I. Jauregui, J. Sastre, and J. Bartra Efficacy of omalizumab in chronic spontaneous urticaria refractory to conventional therapy: analysis of 110 patients in real-life practice Expert Opin Biol Ther 13 2013 1225 1228
75. R.K. Viswanathan, M.H. Moss, and S.K. Mathur Retrospective analysis of the efficacy of omalizumab in chronic refractory urticaria Allergy Asthma Proc 34 2013 446 452
76. R. Vieira Dos Santos, B. Locks Bidese, J. Rabello de Souza, and M. Maurer Effects of omalizumab in a patient with three types of chronic urticaria Br J Dermatol 170 2014 469 471